- Home
- SMTK vs IMRN Comparison
SMTK vs IMRN Comparison
Compare SMTK & IMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SMTK
- IMRN
- Stock Information
- Founded
- SMTK 2009
- IMRN 1994
- Country
- SMTK United Kingdom
- IMRN Australia
- Employees
- SMTK N/A
- IMRN N/A
- Industry
- SMTK
- IMRN Biotechnology: Pharmaceutical Preparations
- Sector
- SMTK
- IMRN Health Care
- Exchange
- SMTK NYSE
- IMRN Nasdaq
- Market Cap
- SMTK 13.3M
- IMRN 15.0M
- IPO Year
- SMTK N/A
- IMRN N/A
- Fundamental
- Price
- SMTK $3.72
- IMRN $2.15
- Analyst Decision
- SMTK
- IMRN Strong Buy
- Analyst Count
- SMTK 0
- IMRN 1
- Target Price
- SMTK N/A
- IMRN $5.00
- AVG Volume (30 Days)
- SMTK 109.9K
- IMRN 21.6K
- Earning Date
- SMTK 02-12-2025
- IMRN 02-26-2025
- Dividend Yield
- SMTK N/A
- IMRN N/A
- EPS Growth
- SMTK N/A
- IMRN N/A
- EPS
- SMTK N/A
- IMRN N/A
- Revenue
- SMTK $40,000.00
- IMRN $3,271,194.00
- Revenue This Year
- SMTK N/A
- IMRN N/A
- Revenue Next Year
- SMTK N/A
- IMRN N/A
- P/E Ratio
- SMTK N/A
- IMRN N/A
- Revenue Growth
- SMTK 471.43
- IMRN 171.67
- 52 Week Low
- SMTK $2.01
- IMRN $1.59
- 52 Week High
- SMTK $13.00
- IMRN $5.96
- Technical
- Relative Strength Index (RSI)
- SMTK N/A
- IMRN 56.18
- Support Level
- SMTK N/A
- IMRN $1.85
- Resistance Level
- SMTK N/A
- IMRN $2.20
- Average True Range (ATR)
- SMTK 0.00
- IMRN 0.22
- MACD
- SMTK 0.00
- IMRN 0.01
- Stochastic Oscillator
- SMTK 0.00
- IMRN 57.47
About SMTK SMARTKEM INC
SmartKem Inc focuses on the design, development, industrialization, and technology transfer of low-temperature, solution-deposited organic semiconductors for transistor backplanes. The company's semiconductor platform can be used in a number of applications including mini-LED displays, AMOLED displays, fingerprint sensors, and logic circuits. The company derives revenue from the sale of TRUFLEX inks and demonstration products.
About IMRN Immuron Limited
Immuron Ltd is a clinical-stage biopharmaceutical company focused on the development and commercialization of a novel class of immunomodulator polyclonal antibodies to treat liver diseases, infectious diseases and other immune-mediated diseases, such as colitis. The company's product, IMM-124E, is a proprietary immunomodulatory agent targeted at GI immune-mediated diseases including fatty liver diseases. The company functions in two segments namely, Research and Development and Hyperimmune products.